Inspire Medical Systems (INSP)
(Delayed Data from NYSE)
$209.36 USD
-1.69 (-0.80%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $209.32 -0.04 (-0.02%) 7:58 PM ET
1-Strong Buy of 5 1
F Value A Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$209.36 USD
-1.69 (-0.80%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $209.32 -0.04 (-0.02%) 7:58 PM ET
1-Strong Buy of 5 1
F Value A Growth B Momentum C VGM
Zacks News
Will These 5 Medical Device Stocks Beat This Earnings Season?
by Zacks Equity Research
Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how INSP, MCK, FMS, NVRO and INGN are placed ahead of their earnings releases.
Gear Up for Inspire (INSP) Q1 Earnings: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of Inspire (INSP) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Here's Why You Should Retain STERIS (STE) Stock for Now
by Zacks Equity Research
STERIS' (STE) strong prospects in the healthcare and pharmaceutical industries bode well for investors.
Haemonetics (HAE) Banks on Plasma Arm Growth Amid Rising Costs
by Zacks Equity Research
Haemonetics' (HAE) hospital portfolio is evolving and helping to create new opportunities for growth and diversification.
Inspire Medical Systems (INSP) Stock Moves -0.8%: What You Should Know
by Zacks Equity Research
Inspire Medical Systems (INSP) closed at $241.66 in the latest trading session, marking a -0.8% move from the prior day.
Here's Why You Should Buy Bruker (BRKR) Stock Right Now
by Zacks Equity Research
Bruker's (BRKR) strong potential across the NANO and BioSpin segments bodes well for investors.
How You Should Play Hologic (HOLX) Ahead of Q2 Earnings
by Riya Anand
Hologic's (HOLX) second-quarter 2024 earnings will likely reflect gains from the GYN surgical business and the growing adoption of Panther instruments.
Amedisys (AMED) Q1 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Amedisys (AMED) tops on revenue and earnings estimates in the first quarter of fiscal 2024.
Edwards Lifesciences (EW) Q1 Earnings Top, 2024 Sales View Up
by Zacks Equity Research
Strong performance of SAPIEN 3 Ultra RESILIA platform and sustainable TAVR growth drives Edwards Lifesciences (EW) Q1 revenues.
Should Lifeward (LFWD) be in Your Portfolio Ahead of Q1 Earnings?
by Moumi Mondal
Lifeward's (LFWD) first-quarter 2024 results are expected to reflect the benefits of several milestone achievements from last year.
ResMed (RMD) Q3 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
ResMed's (RMD) fiscal 2024 third-quarter performance reflects another strong period of execution across the entire business, resulting in impressive top and bottom-line growth.
ICON (ICLR) Q1 Earnings Surpass Estimates, Margins Expand
by Zacks Equity Research
ICON's (ICLR) first-quarter 2024 performance is driven by its efficient service delivery and strong cost control.
Align Technology (ALGN) Q1 Earnings Top, 2024 Sales View Up
by Zacks Equity Research
Align Technology's (ALGN) first quarter 2024 revenue growth was up across all regions and was driven by strong Clear Aligner volumes, primarily in the Asia Pacific region.
Labcorp (LH) Tops Q1 Earnings Estimates, Raises 2024 EPS View
by Zacks Equity Research
Labcorp (LH) sets a strong foundation for the year ahead with its impressive performance in the first quarter of 2024.
Chemed (CHE) Lags Q1 Earnings Estimates, Reaffirms 2024 View
by Zacks Equity Research
Chemed's (CHE) first-quarter 2024 results reflect VITAS' impressive revenue growth and improved average revenues per patient per day.
Thermo Fisher (TMO) Q1 Earnings Top Estimates, 2024 View Up
by Zacks Equity Research
Thermo Fisher's (TMO) first-quarter 2024 revenues register year-over-year growth driven by new product launches.
Boston Scientific (BSX) Q1 Earnings Beat Estimates, View Raised
by Zacks Equity Research
Barring Neuromodulation, organic and operational revenues at Boston Scientific's (BSX) core business segments rise in the first quarter.
Quest Diagnostics (DGX) Q1 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Quest Diagnostics (DGX) continues its strong momentum of base business revenue growth in the first quarter of 2024.
Should You Buy STERIS (STE) Stock Ahead of Q4 Earnings?
by Zacks Equity Research
STERIS (STE) is expected to have witnessed the normalization of the Healthcare backlog, as the company is currently able to ship at a faster pace than the receipt of new orders.
Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Aldeyra Therapeutics, Inc. (ALDX) and Inspire Medical Systems (INSP) have performed compared to their sector so far this year.
What's in the Cards for Zimmer Biomet (ZBH) in Q1 Earnings?
by Zacks Equity Research
Within the Hips business, Zimmer Biomet (ZBH) is expected to have witnessed procedure volume recovery, banking on strategic product launches in the first quarter.
Will Humana (HUM) Q1 Earnings Beat on CenterWell Strength?
by Zacks Equity Research
Humana's (HUM) first-quarter results are likely to reflect rising premiums and investment income.
What Lies Ahead of IDEXX Laboratories (IDXX) in Q1 Earnings?
by Zacks Equity Research
IDEXX Laboratories' (IDXX) first-quarter 2024 results are likely to reflect the benefits of strong execution against the growth strategy.
Here's Why You Should Retain Prestige Consumer (PBH) Stock Now
by Zacks Equity Research
The robust strength of Prestige Consumer's (PBH) diversified portfolio bodes well for investors.
Will High Medical Care Ratios Hurt Molina's (MOH) Q1 Earnings?
by Zacks Equity Research
Molina's (MOH) first-quarter performance is likely to have been hurt by escalating medical care costs, partly offset by growing membership in all three businesses.